The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures
eLife · 21.02.2023 · 12
DOI: 10.7554/elife.82998 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 21.02.2023. Verfasst von Katarína Balážová und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hubrecht Institute for Developmental Biology and Stem Cell Research-KNAW & University Medical Centre Utrecht, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lung Foundation Netherlands.
Abstract (Originalsprache)
Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Traditional therapeutic approaches such as chemotherapy or radiotherapy have provided only a marginal improvement in the treatment of lung carcinomas. Inhibitors targeting specific genetic aberrations present in non-small cell lung cancer (NSCLC), the most common subtype (85%), have improved the prognostic outlook, but due to the complexity of the LC mutational spectrum, only a fraction of patients benefit from these targeted molecular therapies. More recently, the realization that the immune infiltrate surrounding solid tumors can foster tumor-promoting inflammation has led to the development and implementation of anticancer immunotherapies in the clinic. In NSCLC, one of the most abundant leukocyte infiltrates is macrophages. These highly plastic phagocytes, which are part of the cellular repertoire of the innate immunity, can have a pivotal role in early NSCLC establishment, malignant progression, and tumor invasion. Emerging macrophage-targeting therapies have been focused on the re-differentiation of the macrophages toward an antitumorigenic phenotype, depletion of tumor-promoting macrophage subtypes, or combination therapies combining traditional cytotoxic treatments with immunotherapeutic agents. The most extensively used models employed for the exploration of NSCLC biology and therapy have been 2D cell lines and murine models. However, studying cancer immunology requires appropriately complex models. 3D platforms, including organoid models, are quickly advancing powerful tools to study immune cell-epithelial cell interactions within the tumor microenvironment. Co-cultures of immune cells along with NSCLC organoids allow for an in vitro observation of the tumor microenvironment dynamics closely resembling in vivo settings. Ultimately, the implementation of 3D organoid technology into tumor microenvironment-modeling platforms might facilitate the exploration of macrophage-targeted therapies in NSCLC immunotherapeutic research, thus establishing a new frontier in NSCLC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hubrecht Institute for Developmental Biology and Stem Cell Research-KNAW & University Medical Centre Utrecht, Utrecht, Netherlands.
- Oncode Institute, Hubrecht Institute-KNAW, Utrecht, Netherlands.
- Roche Pharma Research and early Development, Basel, Switzerland.
ORCID-Profile: Katarína Balážová, Antonella F M Dost
Förderung
- Lung Foundation Netherlands
Zitieren
APA
Balážová, K., Clevers, H., & Dost, A. F. M. (2023). The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures. eLife, 12. https://doi.org/10.7554/elife.82998
Vancouver
Balážová K, Clevers H, Dost AFM. The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures. eLife. 2023;12. doi:10.7554/elife.82998
BibTeX
@article{Balov2023,
author = {Balážová, Katarína and Clevers, Hans and Dost, Antonella F M},
title = {The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.82998}
}
EUVIMED